EU firms want up to two years to comply with black symbol rule for monitored drugs
This article was originally published in SRA
Pharmaceutical companies and other stakeholders have told the European Commission that they will require a realistic transitional period, possibly up to two years, to fully implement the new requirement for a black symbol to be printed on the product information of medicines subject to additional monitoring1-3. They have also urged the commission to ensure that there is no need to recover or destroy stocks of products or packaging already in the supply chain.
You may also be interested in...
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.